You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

390 Results
Document
Oct 2020
Guidelines and Advice
Status: Current
ID: PET 2020-1
Version: N/A
Nov 2020
Guidelines and Advice
Status: Current
Version: 1.0
Dec 2020
Document
Feb 2021
Document
Feb 2021
Document
May 2021
Guidelines and Advice
Status: Current
ID: PET 2020-2
May 2021
Guidelines and Advice
Status: Current
ID: GL 2-30B
May 2021
Guidelines and Advice
Status: Current
Version: 3.1
Oct 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enfortumab vedotin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
erdafitinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2021

Pages